Enclomiphene
Selective Estrogen Receptor Modulator
Enclomiphene is the trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) that blocks estrogen's negative feedback on the hypothalamus and pituitary, thereby stimulating LH and FSH release and driving endogenous testosterone production. Unlike testosterone replacement, it preserves the HPG axis and maintains fertility.
At a Glance
Standard testosterone replacement therapy (TRT) suppresses the hypothalamic-pituitary-gonadal (HPG) axis — exogenous testosterone signals the brain to stop producing LH and FSH, causing testicular atrophy and infertility. Enclomiphene solves this by blocking estrogen's negative feedback at the pituitary, allowing the natural LH → testosterone cascade to continue.
Phase 2 and 3 trials have confirmed significant testosterone elevation (from hypogonadal levels to mid-normal range) with maintained spermatogenesis — a combination TRT cannot achieve.
Phase 3 NDA was submitted to the FDA. Regulatory status has been complex due to the clomiphene isomer relationship — ongoing as of 2026.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
ER Antagonism at Pituitary
Blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback and allowing increased GnRH, LH, and FSH release.
Endogenous Testosterone Elevation
Elevated LH drives Leydig cell testosterone production — restoring levels through the natural pathway rather than exogenous replacement.
HPG Axis Preservation
Unlike TRT, the entire HPG axis remains active — LH, FSH, and spermatogenesis continue normally throughout treatment.
Fertility Maintenance
FSH maintenance ensures spermatogenesis continues — the key differentiator from TRT for men researching testosterone restoration while maintaining fertility.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Secondary hypogonadism — HPG axis stimulation without TRT suppression
- Male fertility research — testosterone + spermatogenesis preservation simultaneously
- TRT comparison studies — HPG-preserving vs axis-suppressing testosterone restoration
- Post-TRT recovery — HPG axis restart after exogenous testosterone discontinuation
- Aging male testosterone decline — endogenous restoration research
- Testosterone-fertility tradeoff studies — enclomiphene as research model for decoupling the two
- Metabolic effects of testosterone restoration via HPG axis vs exogenous
Enclomiphene vs TRT vs clomiphene defines the three main approaches to testosterone research — each with distinct implications for the HPG axis.
| Aspect | Enclomiphene | Testosterone (TRT) | Clomiphene (racemic) |
|---|---|---|---|
| Mechanism | SERM — HPG axis stimulation | Exogenous replacement | SERM (includes cis-isomer) |
| HPG Axis | Preserved and active | Suppressed | Preserved but less predictable |
| Fertility | Maintained | Lost (during use) | Maintained (less selective) |
| Testosterone Level | Restored to normal range | Supraphysiological possible | Restored (variable) |
| Research Advantage | Clean HPG preservation | Maximum testosterone control | Available but less pure |
HPG axis intact — the only approach that raises testosterone while preserving the entire hypothalamic-pituitary-gonadal cascade
Fertility maintained — spermatogenesis preserved throughout; key differentiator from TRT
Phase 3 clinical data — significant human evidence base from ENFORM trials
Regulatory complexity — NDA process complicated by relationship to clomiphene; approval status evolving
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026